However, in these studies, the inhibition of VEGF-A was initiated prior to the onset of diabetic kidney disease (i.e. prior to the development of albuminuria, glomerular hypertrophy and mesangial expansion/matrix production); thus, whether this strategy is feasible for treating diabetic people with existing kidney damage is currently unknown. The gene discussed is VEGFA; the disease is diabetic kidney disease.